CSTL Castle Biosciences, Inc.

Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.

$69.52  -1.24 (-1.75%)
As of 04/09/2021 15:58:50 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Diagnostics & Research
Index country:  USA
Country of incorporation:  USA
IPO date:  01/04/1999
Outstanding shares:  24,978,424
Average volume:  348,481
Market cap:   $1,736,250,252
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    14843C105
ISIN:        US14843C1053
Sedol:      BKLCWZ3
Valuation   (See tab for details)
PE ratio:   -168.83
PB ratio:   14.42
PS ratio:   27.71
Return on equity:   -2.47%
Net income %:   -16.42%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy